Eagle Pharmaceuticals
Update in progressEGRX (OTC Markets OTCPK)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Eagle Pharmaceuticals, Inc. develops and commercializes medicines for CNS, metabolic critical care, and oncology in the United States. Its portfolio includes RYANODEX for malignant hyperthermia; BELRAPZO and BENDEKA for certain leukemias and indolent B-cell non-Hodgkin’s lymphoma; PEMFEXY for pemetrexed in mesothelioma and NSCLC; BARHEMSYS for PONV; and BYFAVO for procedural sedation. It licenses CAL02 with Combioxin and collaborates on ENA-001, EA-114, and SM-88 with Tyme. Founded 2007, based in Woodcliff Lake, NJ.
Company score
- Sentiment
- 0.06
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.00
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.00
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.03
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketOTC Markets OTCPK (PNK)
- LocationUnited States
- CEOMr. Michael Graves
- Founded2007
- Employees134
- Websitewww.eagleus.com
Identifiers
- ISINUS2697961082
- FIGIBBG005Y3XWH9
- LEI549300TN20OLYTJVP152
- CUSIP269796108
- CIK0000827871